Antidiabetic and Protective Effects of Bioactive Fractions of <i>Abelmoschus ficulneus</i> in Streptozotocin-induced Diabetic Rats

Background: Diabetes mellitus is a chronic metabolic disorder causing hyperglycaemia and organ damage. Limitations of current therapies highlight the need for safer, plant-based alternatives. The antidiabetic and organ-protective potential of Abelmoschus ficulneus remains largely unexplored. Aim: To evaluate the antidiabetic, hepatoprotective, and nephroprotective effects of A. ficulneus leaf extracts and fractions in streptozotocin-induced diabetic rats. Methods: Acute oral toxicity of A. ficulneus leaf extracts was assessed up to 2000 mg/kg. Diabetes was induced in Wistar rats using streptozotocin (60 mg/ kg). Animals were allocated to control, diabetic control, glimepiride-treated, extract-treated, and fraction-treated groups. Blood glucose and body weight were monitored on days 0, 7, 14, and 21. At study completion, blood and urine samples were analysed for renal (serum creatinine, serum total protein, urine total protein) and hepatic (SGPT, SGOT, serum bilirubin) biomarkers using commercial kits. Liver and kidney tissues were examined histopathologically. Results: No mortality or toxicity was observed up to 2000 mg/kg. Streptozotocin caused marked hyperglycaemia (375.17 ± 1.60 vs. 64.16 ± 2.71 mg/dL in controls) and body weight loss (−19.41 ± 0.72 g). Treatment with A. ficulneus significantly reduced blood glucose, with the aqueous extract (200 mg/kg) lowering levels to 99.5 ± 3.69 mg/dL, comparable to glimepiride (97.83 ± 1.04 mg/ dL). Weight loss was attenuated, with methanol fraction AF008-F5 (200 mg/kg) showing the greatest improvement (−0.46 ± 0.02 g). Elevated hepatic markers were significantly reduced by AF008-F5 (SGPT: 52.36 ± 0.52 IU/L, SGOT: 53.51 ± 0.21 IU/L, bilirubin: 1.01 ± 0.01 mg/dL). Histopathological findings confirmed protection against diabetes-induced liver and kidney damage. Conclusion: A. ficulneus leaf extracts, particularly the bioactive methanol fraction AF008-F5, demonstrated significant antihyperglycaemic, hepato

View article page

Download PDF